Montaner JS - Search Results

1

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.

Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM. Veldkamp AI, et al. Among authors: montaner js. AIDS. 2001 Jun 15;15(9):1089-95. doi: 10.1097/00002030-200106150-00003. AIDS. 2001. PMID: 11416710 Clinical Trial.

2

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J; 2NN study group. van Leth F, et al. AIDS. 2005 Mar 25;19(5):463-71. doi: 10.1097/01.aids.0000162334.12815.5b. AIDS. 2005. PMID: 15764851 Clinical Trial.

3

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.

Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D. Raboud JM, et al. Among authors: montaner js. AIDS. 1998 Sep 10;12(13):1619-24. doi: 10.1097/00002030-199813000-00008. AIDS. 1998. PMID: 9764780 Clinical Trial.

4

Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.

Rae S, Raboud JM, Conway B, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D, Montaner JS. Rae S, et al. Among authors: montaner js. AIDS. 1998 Nov 12;12(16):2185-92. doi: 10.1097/00002030-199816000-00014. AIDS. 1998. PMID: 9833860

5

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FW, Hamann D, van der Ende ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F. Pakker NG, et al. Among authors: montaner js. AIDS. 1999 Feb 4;13(2):203-12. doi: 10.1097/00002030-199902040-00008. AIDS. 1999. PMID: 10202826

6

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.

Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, Beijnen JH, Lange JM, Reiss P, Hoetelmans RM. Veldkamp AI, et al. Among authors: montaner js. J Infect Dis. 2001 Jul 1;184(1):37-42. doi: 10.1086/320998. Epub 2001 May 30. J Infect Dis. 2001. PMID: 11398107 Clinical Trial.

7

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.

Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JM, Montaner JS. Conway B, et al. Among authors: montaner js. AIDS. 2001 Jul 6;15(10):1269-74. doi: 10.1097/00002030-200107060-00008. AIDS. 2001. PMID: 11426071 Clinical Trial.

8

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM. Montaner JS, et al. JAMA. 1998 Mar 25;279(12):930-7. doi: 10.1001/jama.279.12.930. JAMA. 1998. PMID: 9544767 Clinical Trial.

9

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.

10

Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies.

de Jong MD, Boucher CA, Cooper DA, Galasso GJ, Gazzard B, Lange JM, Montaner JS, Richman DD, Thomas HC. de Jong MD, et al. Among authors: montaner js. Antiviral Res. 1997 Jul;35(2):65-82. doi: 10.1016/s0166-3542(97)00020-x. Antiviral Res. 1997. PMID: 9217244 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

823 results

Search Page

Filters